Statistics for Phase I/II Study of Spartalizumab (PDR001), An Anti-PD1 Mab, in Patients with Advanced Melanoma or Non-Small Cell Lung Cancer
Total visits
| views | |
|---|---|
| Phase I/II Study of Spartalizumab (PDR001), An Anti-PD1 Mab, in Patients with Advanced Melanoma or Non-Small Cell Lung Cancer | 1 |
Total visits per month
| views | |
|---|---|
| March 2026 | 0 |
| April 2026 | 0 |
| May 2026 | 0 |
| June 2026 | 0 |
| July 2026 | 0 |
| August 2026 | 0 |
| September 2026 | 1 |